Berild & Hviid et al.: "Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries"; the case builds AGAINT COVID jab

by Paul Alexander

increased rate hospital contact due to coagulation disorders & cerebrovascular disease especially for thrombocytopenia & cerebral venous thrombosis post AZD1222 VAX; thromboembolic & thrombocytopenic

Key message as the authors try to sanitize the results:

“there was an increased rate of hospital contacts because of coagulation disorders and cerebrovascular disease, especially for thrombocytopenia and cerebral venous thrombosis, following vaccination with AZD1222. Although increased rates of several thromboembolic and thrombocytopenic outcomes following BNT162b2 and mRNA-1273 vaccination were observed”